Fluoxetine for poststroke depression: A randomized placebo controlled clinical trial

Neural Regeneration Research

Volumn 2, Issue 3, 2007, Pages 162-165

  Kong, Yan ^a   Dong, Wan Li ^a   Liu, Chun Feng ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Depression; Rehabilitation; Serotonin; Stroke

Indexed keywords

ASCORBIC ACID; FLUOXETINE; PLACEBO; SEROTONIN;

ADULT; AGED; ARTICLE; BARTHEL INDEX; CELL LEVEL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HAMILTON SCALE; HUMAN; HYPOMANIA; MAJOR CLINICAL STUDY; MALE; POSTSTROKE DEPRESSION; RANDOMIZED CONTROLLED TRIAL; SOMATIZATION; THROMBOCYTE; UNSPECIFIED SIDE EFFECT;

EID: 77954642037     PISSN: 16735374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1673-5374(07)60036-X     Document Type: Article

References (26)

1. Gainotti G, Antonucci G, Marra C. Relation between depression after stroke, antidepressant therapy, and functional recovery. J Neurol Neurosurg Psychiatry 2001;71(2):258-61
2. Chemerinski E, Robinson RG, Arndt S, et al. The effect of remission of (PSD) on activities of daily living in a double-blind randomized treatment study. J Nerv Ment Dis 2001;189(7):421-5
3. Paolucci S, Antonucci G, Grasso MG, et al. Post-stroke depression, antidepressant treatment and rehabilitation results. A case-control study. Cerebrovasc Dis 2001;12(3):264-71
4. Chemerinski E, Levine SR. Neuropsychiatric disorders following vascular brain injury. Mt Sinai J Med 2006;73(7):1006-14
5. Johnson JL, Minarik PA, Nystrom KV, et al. Poststroke depression incidence and risk factors: an integrative literature review. J Neurosci Nurs 2006;38(4 Suppl):316-27
6. Paul SL, Dewey HM, Sturm JW, et al. Prevalence of depression and use of antidepressant medication at 5-years poststroke in the North East Melbourne Stroke Incidence Study. Stroke 2006;37(11):2854-5
7. Narushima K, Kosier JT, Robinson RG, et al. Preventing poststroke depression: a 12-week double-blind randomized treatment trial and 21-month follow-up. J Nerv Ment Dis 2002;190(5):296-303
8. Fruehwald S, Gatterbauer E, Rehak P, et al. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol 2003;250(3):347-51
9. Rasmussen A, Lunde M, Poulsen DL, et al. A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics 2003;44(3):216-21
10. Niedermaier N, Bohrer E, Schulte K, et al. Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. J Clin Psychiatry 2004;65(12):1619-23
11. Blardi P, Palazzuoli A, de Lalla A, et al. Variations of peripheral markers of serotoninergic system in selected vascular patients. Nutr Metab Cardiovasc Dis 2006;16(3):210-4
12. Blardi P, De Lalla A, Leo A, et al. Serotonin and fluoxetine levels in plasma and platelets after fluoxetine treatment in depressive patients. J Clin Psychopharmacol 2002;22(2):131-6
13. Perez V, Bel N, Celada P, et al. Relationship between blood serotonergic variables, melancholic traits, and response to antidepressant treatments. J Clin Psychopharmacol 1998;18(3): 222-30
14. Pfeffer CR, McBride PA, Anderson GM, et al. Peripheral serotonin measures in prepubertal psychiatric inpatients and normal children: associations with suicidal behavior and its risk factors. Biol Psychiatry 1998;44(7):568-77
15. Williams LS, Ghose SS, Swindle RW. Depression and other mental health diagnoses increase mortality risk after ischemic stroke. Am J Psychiatry 2004;161(6):1090-5
16. Wiart L, Petit H, Joseph PA, et al. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 2000;31(8):1829-32
17. Rampello L, Battaglia G, Raffaele R, et al. Is it safe to use antidepressants after a stroke? Expert Opin Drug Saf 2005;4(5): 885-97
18. Kimura M, Kanetani K, Imai R, et al. Therapeutic effects of milnacipran, a serotonin and noradrenaline reuptake inhibitor, on post-stroke depression. Int Clin Psychopharmacol 2002;17(3):121-5
19. Ramasubbu R, Tobias R, Buchan AM, et al. Serotonin transporter gene promoter region polymorphism associated with poststroke major depression. J Neuropsychiatry Clin Neurosci 2006;18(1):96-9
20. Maurer-Spurej E, Pittendreigh C, Misri S. Platelet serotonin levels support depression scores for women with postpartum depression. J Psychiatry Neurosci 2007;32(1):23-9
21. Axelson DA, Perel JM, Birmaher B, et al. Platelet serotonin reuptake inhibition and response to SSRIs in depressed adolescents. Am J Psychiatry 2005;162:802-4
22. Spalletta G, Bossu P, Ciaramella A, et al. The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines. Mol Psychiatry 2006;11(11): 984-91
23. Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J Clin Psychiatry 2004; 65(12):1642-53
24. Kim JS, Choi S, Kwon SU, et al. Inability to control anger or aggression after stroke. Neurology 2002;58(7):1106-8
25. Choi-Kwon S, Han SW, Kwon SU, et al. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke 2006; 37(1):156-61
26. Choi-Kwon S, Kim HS, Kwon SU, et al. Factors affecting the burden on caregivers of stroke survivors in South Korea. Arch Phys Med Rehabil 2005;86(5):1043-8